Zobrazeno 1 - 10
of 412
pro vyhledávání: '"John D. Shaughnessy"'
Autor:
Jian-rong Li, Shahram Arsang-Jang, Yan Cheng, Fumou Sun, Anita D’Souza, Binod Dhakal, Parameswaran Hari, Quillan Huang, Paul Auer, Yong Li, Raul Urrutia, Fenghuang Zhan, John D. Shaughnessy, Siegfried Janz, Jing Dong, Chao Cheng
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Multiple myeloma (MM) is a heterogenous plasma cell malignancy, for which the established prognostic models exhibit limitations in capturing the full spectrum of outcome variability. Leveraging single-cell RNA-sequencing data, we developed a
Externí odkaz:
https://doaj.org/article/82447a8befb941718ae624e1ab75d3e4
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Autor:
Wancheng Guo, Yihao Zhan, David Mery, Eric R. Siegel, Fumou Sun, Yan Cheng, Timothy Cody Ashby, Zijun Zhang, Clyde Bailey, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/f59b8168c4bc41abb2bfff80fe089e06
Autor:
Fumou Sun, Yan Cheng, Visanu Wanchai, Wancheng Guo, David Mery, Hongwei Xu, Dongzheng Gai, Eric Siegel, Clyde Bailey, Cody Ashby, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Yupo Ma, Qing Yi, Robert Z. Orlowski, Maurizio Zangari, Frits van Rhee, Siegfried Janz, Gail Bishop, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy with high response rates in myeloma. However, durable cures following anti-BCMA CAR-T c
Externí odkaz:
https://doaj.org/article/68fd54c5690048f79c63bc21afccca4b
Autor:
Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Siegfried Janz, Bart Barlogie, Frits Van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)
Abstract Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting MGUS progression has not been p
Externí odkaz:
https://doaj.org/article/06fafe2671dd496cac7b712408124b7b
Autor:
Faris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D. Shaughnessy Jr, Fenghuang Zhan, Frits vanRhee, Samer Al Hadidi
Publikováno v:
eJHaem, Vol 4, Iss 2, Pp 454-458 (2023)
Abstract The definition of high‐risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme v
Externí odkaz:
https://doaj.org/article/092efc3f964b4af8aef42ba95eaf4704
Autor:
Dongzheng Gai, Jin-Ran Chen, James P. Stewart, Intawat Nookaew, Hasem Habelhah, Cody Ashby, Fumou Sun, Yan Cheng, Can Li, Hongwei Xu, Bailu Peng, Tarun K. Garg, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Fangping Chen, Bart Barlogie, Frits van Rhee, Guido Tricot, John D. Shaughnessy Jr., Fenghuang Zhan
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 18 (2022)
Osteolytic bone disease is a hallmark of multiple myeloma (MM). A significant fraction (~20%) of MM patients do not develop osteolytic lesions (OLs). The molecular basis for the absence of bone disease in MM is not understood. We combined PET-CT and
Externí odkaz:
https://doaj.org/article/e0033236077b4a64b805c9d221f71dcc
Autor:
Tarun K. Garg, Susann M. Szmania, Junaid A. Khan, Antje Hoering, Paul A. Malbrough, Amberly Moreno-Bost, Amy D. Greenway, Joshuah D. Lingo, Xin Li, Shmuel Yaccoby, Larry J. Suva, Brian Storrie, Guido Tricot, Dario Campana, John D. Shaughnessy, Bijay P. Nair, William T. Bellamy, Joshua Epstein, Bart Barlogie, Frits van Rhee
Publikováno v:
Haematologica, Vol 97, Iss 9 (2012)
Background Patients with gene expression profiling-defined high-risk myeloma in relapse have poor outcomes with current therapies. We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound
Externí odkaz:
https://doaj.org/article/43e308d104fa406da5162d5351f878a6
Autor:
Dirk Hose, Thierry Rème, Thomas Hielscher, Jérôme Moreaux, Tobias Messner, Anja Seckinger, Axel Benner, John D. Shaughnessy, Bart Barlogie, Yiming Zhou, Jens Hillengass, Uta Bertsch, Kai Neben, Thomas Möhler, Jean François Rossi, Anna Jauch, Bernard Klein, Hartmut Goldschmidt
Publikováno v:
Haematologica, Vol 96, Iss 1 (2011)
Background Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin polymerase inhibitors) and upcoming (e.g. aurora kinase inhibitors) compounds.Design
Externí odkaz:
https://doaj.org/article/4bff6fb7a2514ee8820850615ab98817
Autor:
Bart Barlogie, John Crowley, Antje Hoering, Joshua Epstein, Clyde Bailey, Nathan Petty, Yazan Alsayed, Sarah Waheed, Bijay Nair, Elias Anaissie, Frits van Rhee, Saad Z. Usmani, John D. Shaughnessy, Emily Hansen, Jackie Szymonifka, Christoph J. Heuck
PDF file, 256K, Thalidomide effect on overall and progression-free survival according to glucocorticoid receptor (NR3C1) expression level.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48cc1284a2e4fc166e4e3a8f7ae5385e
https://doi.org/10.1158/1078-0432.22454750.v1
https://doi.org/10.1158/1078-0432.22454750.v1
Autor:
Bart Barlogie, Guido Tricot, Antje Hoering, Yazan Alsayed, Abid Mohiuddin, Klaus Hollmig, Maurizio Zangari, Mauricio Pineda-Roman, Elias Anaissie, Frits van Rhee, Joshua Epstein, John Crowley, Fenghuang Zhan, John D. Shaughnessy, Jeffrey Haessler
Supplementary Data from Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d713942d4fd9cfb0f5a802e4bb8bb4
https://doi.org/10.1158/1078-0432.22441171
https://doi.org/10.1158/1078-0432.22441171